ARTICLE | Discovery & Translation
Moderna Genomics: the start-up–like unit leveraging RNA for gene editing
Through deals and internal innovation, Moderna is building a gene editing unit with the goal of treating all monogenic liver diseases
April 11, 2023 4:36 PM UTC
Separate from its pipeline of RNA vaccines and therapies, Moderna is building a semi-autonomous unit tasked with developing the company’s signature modality as a vehicle for gene editing machinery.
The “lofty but reachable goal” of the Moderna Genomics unit at Moderna Inc. (NASDAQ:MRNA) is to treat “everyone with monogenic liver diseases” via platforms conducive to n-of-one therapies, said Eric Huang, the division’s general manager and CSO. “All the pieces are there,” he told BioCentury...